These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35044093)

  • 21. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
    Wong A; Riley M; Zhao S; Zimmer J; Viveiros M; Wang JG; Esguerra V; Li M; Lopez G; Kendra K; Carbone DP; He K; Alahmadi A; Kaufman J; Memmott RM; Shields PG; Brownstein J; Haglund K; Welliver M; Otterson GA; Presley CJ; Wei L; Owen DH; Ho K
    J Natl Compr Canc Netw; 2023 Nov; 21(11):1164-1171.e5. PubMed ID: 37935100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang L; Li B; Xu Y; Zou B; Fan B; Wang C; Wang L
    Future Oncol; 2023 May; 19(16):1151-1160. PubMed ID: 37293787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer.
    Sumi T; Sekikawa M; Koshino Y; Nagayama D; Nagahisa Y; Matsuura K; Shijubou N; Kamada K; Suzuki K; Ikeda T; Michimata H; Watanabe H; Yamada Y; Osuda K; Tanaka Y; Chiba H
    Thorac Cancer; 2024 Jul; 15(20):1572-1581. PubMed ID: 38828610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes.
    Banavasi H; Kim S; Alkassis S; Daoud A; Laktineh A; Nagasaka M; Sukari A; Soubani AO
    Hematol Oncol Stem Cell Ther; 2023 Jan; 16(2):144-150. PubMed ID: 34688626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world incidence and risk factors of pneumonitis in chemoradiation plus immune checkpoint inhibitors compared with chemoradiation alone in lung cancer: a retrospective cohort study.
    Pu D; Liu Q; Zhang S; Wang L; Xu F; Hofman P; Giusti R; Zhou Q; Li X; Li L
    Transl Lung Cancer Res; 2024 Jan; 13(1):139-151. PubMed ID: 38405001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis.
    Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Hanai N; Muro K; Hida T
    BMC Cancer; 2021 Aug; 21(1):924. PubMed ID: 34399710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy.
    Kitahara Y; Inoue Y; Yasui H; Karayama M; Suzuki Y; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Funai K; Honda T; Misawa K; Miyake H; Takeuchi H; Inui N; Suda T
    Respir Res; 2024 Jan; 25(1):25. PubMed ID: 38200501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.
    Shibaki R; Murakami S; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Kusumoto M; Yamamoto N; Ohe Y
    Cancer Immunol Immunother; 2020 Jan; 69(1):15-22. PubMed ID: 31745589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
    BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities.
    Kikuchi R; Watanabe Y; Okuma T; Nakamura H; Abe S
    Cancer Immunol Immunother; 2024 Sep; 73(11):211. PubMed ID: 39235641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
    Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer.
    Peiliang Wang MD; Yikun Li MM; Mengyu Zhao MM; Jinming Yu MD; Feifei Teng MD
    Int Immunopharmacol; 2024 Feb; 128():111489. PubMed ID: 38266450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pre-treatment with EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database.
    Okada N; Hamano H; Yagi K; Niimura T; Aizawa F; Goda M; Zamami Y; Kitahara T; Ishizawa K
    Int J Clin Pharmacol Ther; 2024 Feb; 62(2):69-76. PubMed ID: 37969096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.
    Kanai O; Kim YH; Demura Y; Kanai M; Ito T; Fujita K; Yoshida H; Akai M; Mio T; Hirai T
    Thorac Cancer; 2018 Jul; 9(7):847-855. PubMed ID: 29782069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer.
    Altan M; Soto F; Xu T; Wilson N; Franco-Vega MC; Simbaqueba Clavijo CA; Shannon VR; Faiz SA; Gandhi S; Lin SH; Lopez P; Zhong L; Akhmedzhanov F; Godoy MCB; Shroff GS; Wu J; Khawaja F; Kim ST; Naing A; Heymach JV; Daniel-Macdougall C; Liao Z; Sheshadri A
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):630-639. PubMed ID: 37507279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
    Fujimoto D; Miura S; Yoshimura K; Wakuda K; Oya Y; Yokoyama T; Yokoi T; Asao T; Tamiya M; Nakamura A; Yoshioka H; Haratani K; Teraoka S; Tokito T; Murakami S; Tamiya A; Itoh S; Yokouchi H; Watanabe S; Yamaguchi O; Tomii K; Yamamoto N
    Eur J Cancer; 2021 Jun; 150():63-72. PubMed ID: 33892408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
    Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
    Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.
    Cousin F; Desir C; Ben Mustapha S; Mievis C; Coucke P; Hustinx R
    Radiother Oncol; 2021 Apr; 157():47-55. PubMed ID: 33453313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.